BioSpace News Archive

Another Kevzara study in hospitalized COVID-19 patients failed to meet primary and secondary endpoints.

The primary endpoint was triglyceride reduction at 12 and 26 weeks. The trial evaluated 278 patients.

According to new data from the EAST-AFNET 4 trial that was released on Aug. 29, patients with atrial fibrillation appear to benefit from early rhythm control therapy.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 2, 2020.

The rolling NDA was somewhat expected after an end-of-phase meeting with the FDA earlier this year turned into a pre-NDA meeting with the regulatory agency.

The U.S. expansion will recruit up to 30,000 adults over the age of 18 years from a broad range of racial, ethnic and geographic groups who are healthy or have stable underlying medical conditions.

Lumen Biosciences closed a $16 million Series B funding round that will support the development of its three clinical programs aimed at C. difficile, norovirus and traveler’s diarrhea.

The COVID-19 pandemic is changing the FDA irrevocably, resulting in a more dynamic, streamlined FDA that is more willing to embrace digital technology, according to panelists at the recent OC LIFe (Lifesciences Innovators Forum) virtual presentation, “COVID-19: Changes In FDA Approval & Clearance Processes.”

In a groundbreaking new study, scientists at Harvard University have identified one enzyme that seems to dictate the limits of our physical performance.

Are you willing to relocate internationally to further your career? It can be a difficult decision with much to consider including language, cultural and industry differences.